癌痛患者多维BTS评估量表的构建及信效度检验

摘要:

目的：本研究旨在构建适合癌痛患者的疼痛评估量表，并探索评估量表用于癌痛患者的信度和效度，以期为临床癌痛患者的管理提供更加简便易行的评估工具。方法：2022年3月，基于国内癌痛领域的指导性规范、指南和共识和专家讨论意见，构建了癌痛患者评估量表初始条目池，采取德尔菲法选取我国相关领域的二十余名专家进行两轮咨询，统计咨询结果，确认纳入的条目，形成最终的多维BTS（Botong Score）评估量表。2022年6月-2023年2月，在北部战区总医院纳入癌痛患者，使用构建的BTS评估量表进行信效度检验。结果：经过两轮德尔菲法专家咨询，第一轮纳入21位专家，第二轮纳入10位专家，第一轮纳入19个评估维度，选取重要性评分≥4.5分且变异系数≤20%的7个评估维度，进行第二轮问询。这7个评估维度和条目的重要性结果与第一轮一致，由此最终构建的BTS评估量表共包含7个评估维度，15个条目。北部战区总医院共纳入166例患者，经过数据清洗，最终纳入分析的患者例数为138例。BTS的信度检测Cronbach α系数为0.781，效度检测的KMO值为0.796，具有较好的信度和效度。结论：经过两轮德尔菲法专家咨询，构建的BTS评估量表条目共纳入7个评估维度，15个条目，具有较好的信度和效度，可在临床实践中推广应用于癌痛患者的疼痛评估。

Abstract:

Objective: This research is aimed to construct the pain evaluation scale suitable to cancer-related pain patients, and explore its reliability and validity in cancer-related pain patients, to provide more simple and practical tools for management of cancer-related pain patients in clinical settings.Methods: Based on Chinese guidance, consensus, recommendations in cancer-related pain field and discussions from experts in this field, we constructed the initial item pool, and consulted with more than twenty experts in this field according to Delphi methodology. After 2 rounds of consultations from experts, the inclusion of items were confirmed and formed the final multi-dimensional BTS (Botong Score) scales. During June 2022 to February 2023, we enrolled the cancer-related pain patients in General Hospital of Northern Theater Command, and test the reliability and validity of this scale.Results: After 2 rounds of Delphi expert consultations, the first round enrolled 21 experts, and the second round enrolled 10 experts. The scale in the first round included 19 dimensions, selected 7 dimensions with importance score ≥4.5 and the coefficient of variation ≤20%, which advanced in the second round. The final BTS evaluation scale was consisted of these 7 dimensions, 15 items with the importance score consistent in these two rounds. In General Hospital of Northern Theater Command, we enrolled 166 patients, after final data cleaning, 138 patients were included in the final analysis. The reliability and validity of BTS was tested and proven to be good, with Cronbach α coefficient of 0.781 and KMO value of 0.796.Conclusion: After 2 rounds of Delphi expert consultations, the multi-dimensional BTS evaluation scale included 7 dimensions and 15 items, with good reliability and validity, with great potential to apply in the cancer-related pain patients in clinical settings.